Friday

08:30 - 10:30 HALL
H3:	ONCOLOGY Capsule: Conservative Management of Gynecology Oncology.
	Chairpersons:	J. Chambers, USA R. Dgani, Israel L. Rob, Czech Republic
	08:30	CERVICAL CARCINOMA: HOW TO TREAT DURING REPRODUCTIVE YEARS? D.F.G. D'Argent, France
	09:00	OVARIAN CANCER: THE PLACE OF CONSERVATIVE SURGERY: LIMITATION IN PATHOLOGICAL EVALUATION J. Chambers, USA
	09:30	ENDOMETRIAL CANCER: ASYMPTOMATIC ENDOMETRIAL FINDINGS AND OVARIAN CYSTS DURING MEOPAUSE U. Beller, Israel
	10:00	ALTERNATIVE MEDICINE S. Granai, USA
	10:30	Coffee Break
11:00 - 13:00 HALL A
H2:	LAPAROSCOPY IN GYNECOLOGIC ONCOLOGY Capsule: Laparoscopic Oncology, is it the end of Laparotomy?
	Chairpersons:	S. Granai, USA U. Beller, Israel J. Chambers, USA
	11:00	IS THERE A PLACE FOR LAPAROSCOPIC SURGERY IN GYNECOLOGY ONCOLOGY? E.A. Surwit, USA
	11:30	LYMPH ADENECTOMY: LAPAROSCOPY VS LAPAROTOMY T. Levy, Israel
	12:00	THE USE OF LAPAROSCOPY IN THE MANAGEMENT OF THE ADNEXAL MASS D.F.G. D'Argent, France
	12:30	COMBINED LAPAROSCOPY AND VAGINAL SURGERY E.A. Surwit, USA
	13:00	Lunch Break
	13:30	Special Lecture FETAL CELLS IN MATERNAL CIRCULATION - THEIR ROLE FOR NON INVASIVE PRENATAL DIAGNOSIS AND IN CERTAIN MATERNAL DISEASES W. Holzgreve, Switzerland
14:30 - 16:00 HALL A
H1:	OVARIAN CANCER Capsule: The ovaries are the least accessible of the pelvic organs and hence delayed diagnosis is usually the rule. Can mass screening be cost effective?
	Chairpersons:	E.A. Surwit, USA I.E. Timor, USA T. Levy, Israel
	14:30	SHOULD A MASS SCREENING PROGRAM BE IMPLEMENTED FOR OVARIAN CANCER? I. Jacobs, UK
	15:00	THE ROLE AND LIMIT OF VAGINAL DOPPLER ULTRASOUND IN OVARIAN CANCER A. Kurjak, Croatia
	15:30	BIOCHEMICAL AND ULTRASOUND SCREENING - COST EFFECTIVE? I. Jacobs, UK
	16:00	Coffee Break
16:30 - 18:00 HALL A
D2:	HRT DIFFERENT MODE OF HORMONAL TREATMENT Capsule: Despite over 30 years of use, many questions are still unanswered. Sponsored by: Hoechst Marion Roussel
	Chairpersons:	R. Sitruk-Ware, France A. Volpe, Italy R.F. Casper, Canada
	16:30	HRT FOR ALL - TO DOSE OR OVERDOSE? A.R. Genazzani, Italy
	16:48	THE IDEAL TIMING TO START AND STOP: CONTRADICTION FOR TREATMENT? J. Studd, UK
	17:06	HORMONAL REPLACEMENT THERAPY: TO BLEED OR NOT TO BLEED R.F. Casper, Canada
	17:24	PILLS, DERMAL JELL OR PATCHES? R. Sitruk-Ware, France
	17:42	NEW PROGESTIN - HOW STRONG IS THE EVIDENCE - THE CASE OF TRIMEGESTONE F. Al-Azzawi, UK
18:00 - 19:30 HALL A
D4:	OSTEOPOROSIS: DIAGNOSIS & TREATMENT Capsule: With increasing life expectancy, Osteoporosis is becoming a true Epidemiic
	Chairpersons:	U.A. Liberman, Israel J. Studd, UK M. Szamatowicz, Poland
	18:00	BIOCHEMICAL MARKERS OF BONE TURN-OVER U.A. Liberman, Israel
	18:22	RADIOLOGY AND ULTRASOUND D. Hans, Switzerland
	18:44	PREVENTION WITH DRUGS OTHER THAN HRT: BISPHOSPHONATE U.A. Liberman, Israel
	19:06	SELECTING THE ESTROGEN FOR TREATMENT J. Studd, UK
08:30 - 10:30 HALL B + C
A1:	IMPLANTATION Capsule: The most crucial step in IVF success is implantation. Can implantation be improved?
	Chairpersons:	J.G. Schenker, Israel R.G. Gosden, UK M.J. Tucker, USA
	08:30	UTERLINE FACTORS S.L. Tan, Canada
	08:50	THE VALUE OF LUTEAL SUPPORT S.H. Daya, Canada
	09:10	ROLE OF HATCHING M.J. Tucker, USA
	09:30	IS BLASTOCYSTS THE ANSWER? D.K. Gardner, USA
	09:50	IS CULTURING MEDIUM IMPORTANT? P. Guerin, France
	10:10	MARKERS OF VIABILITY D.K. Gardner, USA
	10:30	Coffee Break
11:00 - 13:00 HALL B + C
A2:	CONTROVERSIES IN OVULATION INDUCTION Capsule: The debate continues, is LH useful for COH? Sponsored by: Ferring Pharmaceuticals
	Chairperson:	M. Filicori, Italy R. Homburg, Israel
		GONADOTROPIN STIMULATION REGIMENS AND OOCYTE EMBRYO QUALITY U. Gordon, UK
		EFFECTS OF DIFFERENT GONADOTROPIN PREPARATIONS IN THE MANAGEMENT OF ANOVULATION R. Homburg, Israel
		ROLE OF LH ACTIVITY IN THE STIMULATION OF MULTIPLE FOLLICULOGENESES M. Filicori, Italy
		MENOTROPIN LH CONTENT AND ASSISTED REPRODUCTION OUTCOME L. Westergaard, Denmark
	13:00	Lunch Break
14:30 - 16:00 HALL B + C
A5:	OVULATION INDUCTION & STIMULATION PROTOCOLS WITH rFSH Capsule: Is rFSH better than the urinary alternatives? (an interactive session) Sponsored by: Ares-Serono
	Chairperson:	H.S. Jacobs, UK
		INTRODUCTION - PROS AND CONS OF META-ANALYSIS H.S. Jacobs, UK
		WHAT IS THE EVIDENCE THAT rFSH IS BETTER THAN uFSH? S.H. Daya, Canada
	16:00	Coffee Break
16:30 - 18:00 HALL B + C
A4:	CETROTIDE IN DAILY CLINICAL PRACTICE Capsule: To agonize or antagonize? Sponsored by: Ares-Serono and ASTA Medica
	Chairpersons:	K. Diedrich, Germany J. Schoemaker, The Netherlands
		AGONISTS VS ANTAGONISTS: WHERE ARE WE TODAY? C.B. Lambalk, The Netherlands
		Cetrotide MULTIDOSE PROTOCOL: RESULTS OF THE LARGEST MULTINATIONAL STUDY WITH AN ANTAGONIST IN ART P. Devroey, Belgium
		CETROTIDE: SIMPLIFYING CLINICAL PRACTICE M. Wikland, Sweden
18:00 - 19:30 HALL B + C
A3a:	ENDOMETRIOSIS Capsule: A perplexing, poorly understood disease of the female reproductive system.
	Chairpersons:	B. Tarlatzis, Greece J.L.H. Evers, The Netherlands L. Mettler, Germany
	18:00	STAGES OF ENDOMETRIOSIS: DOES IT AFFECT THE SUCCESS OF IVF? S.L. Tan, Canada
	18:18	IS IVF THE ONLY VIABLE TREATMENT? J.L.H. Evers, The Netherlands
	18:36	STAGE I AND II: TO TREAT OR NOT TO TREAT? P. Koninckx, Belgium
	18:54	SURGERY VS PHARMACOLOGICAL TREATMENT - IS IT STAGE DEPENDENT? (PHARMACOLOGY) S.K. Smith, UK
	19:12	SURGERY VS. PHARMACOLOGICAL TREATMENT - IS IT STAGE DEPENDENT? (SURGERY) P. Koninckx, Belgium